DropGenie Secures Seed+ Financing to Launch Miniaturized Gene Editing Platform for Primary Cell Applications
核心洞察
DropGenie (搜索) closed a Seed+ financing round led by Skeleton Key (搜索), with Merck Global Health Innovation Fund (搜索) and CQDM (搜索) joining as new investors to support the commercial launch of its gene editing platform.
The platform miniaturizes gene editing workflows, reducing cell and reagent requirements to enable direct editing of primary patient cells for more biologically relevant data earlier in R&D.
Funding will scale manufacturing, build commercial operations, and accelerate adoption among pharmaceutical, biotechnology, and research organizations following successful validation through an Early Access Program.
DropGenie (搜索), a biotechnology company with operations in Montreal and Boston, has closed a Seed+ financing round to support the commercial launch of its next-generation gene editing platform. The round was led by Skeleton Key (搜索), with new investors Merck Global Health Innovation Fund (搜索) and CQDM (搜索) joining existing backers Real Ventures (搜索) and Anges Québec (搜索). Financial terms were not disclosed.
The funding marks a pivotal transition for the company as it moves from product development and validation into full-scale commercialization. Capital will be directed toward scaling manufacturing capabilities, building commercial operations, and accelerating customer adoption across pharmaceutical, biotechnology, and research organizations.
Platform Technology and Capabilities
DropGenie (搜索)'s platform is designed to improve the efficiency of gene editing experiments through miniaturized, high-throughput workflows that significantly reduce the number of cells and reagents required per experiment. This approach lowers experimental costs while shortening turnaround times, enabling researchers to conduct larger-scale studies with fewer biological materials.
A defining feature of the technology is its ability to facilitate direct gene editing in primary patient cells. By dramatically reducing cell requirements, the platform allows researchers to work directly with clinically relevant cell types, generating biological data that has historically been difficult to obtain at scale. The company positions this capability as having applications across cell therapy development, functional genomics research, and emerging AI-enabled drug discovery initiatives.
"The most powerful insights in biology come from perturbations—changing one thing and watching how a living system responds. But capturing those signals with fidelity demands working at the right scale, in the right cells," said Alison Hirukawa, CEO and Co-founder of DropGenie (搜索). "Our platform miniaturizes workflows and lowers cell requirements to enable direct editing of primary patient cells—giving researchers access to true biological readouts previously impossible to capture."
Early Access Program Validation
The commercial launch follows successful validation through DropGenie (搜索)'s Early Access Program, during which the platform was adopted by major global pharmaceutical companies, biotechnology firms, and research institutions. According to the company, a number of early customers have already integrated the technology into their research workflows, providing real-world evidence of the platform's utility prior to the broader market rollout.
Investor Perspective
Ann Lai, Managing Partner of Skeleton Key (搜索), emphasized the strategic value of the platform's data generation capabilities: "Being able to capture every parameter variation of these complex gene editing experimental processes creates the data we need to fundamentally accelerate innovation and to better leverage AI beyond the theoretical discovery phases."
Lai added that the firm's investment was driven by the technology's ability to automate and miniaturize complex experimental processes while generating datasets that can support future innovation.
Strategic Data Partnerships and AI Integration
Beyond product commercialization, the Seed+ financing will support strategic data partnerships with customers. DropGenie (搜索) plans to work with industry partners to generate standardized gene editing datasets that can be used to support data-driven research initiatives and improve biological discovery efforts. The company believes its workflow efficiency creates an opportunity to produce foundational datasets at scale—a capability that is becoming increasingly valuable as biotechnology companies incorporate artificial intelligence and machine learning tools into drug discovery and therapeutic development programs.
As the life sciences industry places greater emphasis on high-quality biological data and predictive research models, DropGenie (搜索)'s platform is designed to address a growing need for scalable experimental infrastructure. By reducing resource requirements while improving access to biologically relevant data, the company aims to help researchers accelerate development timelines and improve decision-making across a range of therapeutic applications.